Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma

Sven H. Loosen, Christoph Roderburg, Katja L. Kauertz, Inês Pombeiro, Catherine Leyh, Fabian Benz, Mihael Vucur, Thomas Longerich, Alexander Koch, Till Braunschweig, Tom F. Ulmer, Christoph Heidenhain, Frank Tacke, Marcel Binnebösel, Maximilian Schmeding, Christian Trautwein, Ulf P. Neumann, Tom Luedde

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

Background & Aims Cholangiocarcinoma (CCA) represents a primary hepatic malignancy with incidence and mortality rising globally. Surgical treatment has remained the only potentially curative treatment option, but it is still unclear which patients benefit most from extended liver surgery, highlighting the need for new pre-operative stratification strategies. Osteopontin is a secreted extracellular glyco-phosphoprotein that has been associated with inflammation, metabolic disorders and cancer. Here, we examined the potential of circulating osteopontin serum levels as a diagnostic or prognostic biomarker in patients with CCA undergoing extended liver surgery. Methods Osteopontin expression levels were analysed in human and murine CCA tumour samples, using semi-quantitative reverse transcriptase PCR and immunohistochemistry. Osteopontin serum concentrations were measured by enzyme-linked immunosorbent assay in 107 patients with CCA undergoing elective tumour resection as well as 55 healthy controls. Results were correlated with clinical data. Results Correlating with an upregulation in CCA tumour cells and the tumour stroma, serum levels of osteopontin were elevated in patients with cholangiocarcinoma compared to healthy controls and patients with primary sclerosing cholangitis. Importantly, pre- and postoperative elevations of osteopontin showed a striking association with poor postoperative survival. Conclusions Serum osteopontin concentrations represent a promising prognostic biomarker in patients resectable CCA which could help to guide preoperative treatment decisions and to identify patients that will particularly benefit from extended liver surgery. Lay summary: Extended liver surgery is the only potentially curative treatment for patients with cholangiocarcinoma (CCA/biliary cancer), but it is currently unclear which patients benefit most from surgery. Detecting serum levels of osteopontin – a specific secreted glycoprotein involved in multiple human diseases – in CCA patients might help to identify those patients that particularly benefit from tumour resection.

Original languageEnglish
Pages (from-to)749-757
Number of pages9
JournalJournal of Hepatology
Volume67
Issue number4
DOIs
StatePublished - Oct 2017
Externally publishedYes

Keywords

  • Biomarker
  • CA19-9
  • CCA
  • CEA
  • Cancer
  • Osteopontin
  • Prognosis

Fingerprint

Dive into the research topics of 'Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this